Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07695532

A Clinical Risk Score to Stratify High-risk PanNETs

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

Considerable heterogeneity exists in the risk of recurrence after curative resection of pancreatic neuroendocrine tumors (PanNETs). Current clinicopathological parameters (e.g., grade, TNM stage) have limited capacity for individualized risk stratification. There is an urgent need for a clinically accessible and operationally simple predictive tools to identify high-risk PanNETs for optimizing personalized postoperative treatment and follow-up strategies. This study aims to identify risk factors associated with recurrence of PanNETs and to develop a clinically applicable risk stratification tool based on multi-center cohorts and multi-omics validation for identifying high-risk patients.

Official title: A Clinically Applicable Risk Score for Identifying High-risk Pancreatic Neuroendocrine Tumors: Development, Validation, and Biological Correlates

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

552

Start Date

2017-06-01

Completion Date

2026-07-01

Last Updated

2026-07-10

Healthy Volunteers

No

Interventions

PROCEDURE

Curative surgical resection

After pathological confirmation of pancreatic neuroendocrine neoplasm, the patient underwent radical surgery.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China